Biotech firm Kyowa Hakko Kirin (Kyowa) announced on 25 January 2016 that it had made a deal with Sandoz, the generics division of Novartis, for exclusive marketing rights to Sandoz’s biosimilar rituximab in Japan.
- Home
-
Generics
News
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
-
Biosimilars
News
- Clinical study advances for Alvotech golimumab and Dr Reddy’s rituximab biosimilars
- New insulin glargine and potential adalimumab interchangeable biosimilars
- Biosimilar advances for Alvotech-Teva and setback for Biocon Biologics
- Advances for Bio-Thera’s secukinumab and mepolizumab copy biologicals
Research
- Best-value biological selection making: more to consider than only price
- US vs Germany and Switzerland: US biosimilars market lags with higher prices
- Drug survival of adalimumab biosimilars in psoriasis treatment in Spain
- Pegfilgrastim biosimilars in US supportive oncology
- MORE EDITORIAL SECTIONS
- Search
Post your comment